- Home
- CRIS vs CTXR Comparison
CRIS vs CTXR Comparison
Compare CRIS & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRIS | CTXR |
|---|---|---|
| Founded | 2000 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.6M | 18.9M |
| IPO Year | 2000 | 2010 |
Fundamental Metrics
Financial Performance| Metric | CRIS | CTXR |
|---|---|---|
| Price | $4.63 | $0.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $17.00 | $6.00 |
| AVG Volume (30 Days) | ★ 7.6M | 191.1K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.57 | 43.38 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,898,000.00 | N/A |
| Revenue This Year | $27.10 | N/A |
| Revenue Next Year | $67.74 | $147.57 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 31.50 | N/A |
| 52 Week Low | $0.18 | $0.48 |
| 52 Week High | $6.74 | $2.19 |
Technical Indicators
Market Signals| Indicator | CRIS | CTXR |
|---|---|---|
| Relative Strength Index (RSI) | 73.85 | 41.13 |
| Support Level | $0.75 | $0.48 |
| Resistance Level | $6.74 | $0.62 |
| Average True Range (ATR) | 0.44 | 0.04 |
| MACD | 0.30 | -0.00 |
| Stochastic Oscillator | 66.77 | 6.92 |
Price Performance
Historical ComparisonAbout CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About CTXR Citius Pharmaceuticals Inc.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.